Building on previous reports on lysosomal deficiency in models of AD (Hung & Livesey, 2018), and the involvement of CASP6 in induction of LB1 degradation (Islam et al., 2019), in this study, we aimed to examine the involvement of lysosomal enzymes in NL damage and assess its potential amenability to pharmacological interventions. Here, CASP6 is linked to Alzheimer disease.